- Home
- GOCO vs GNLX Comparison
GOCO vs GNLX Comparison
Compare GOCO & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOCO
- GNLX
- Stock Information
- Founded
- GOCO 2001
- GNLX 2001
- Country
- GOCO United States
- GNLX United States
- Employees
- GOCO N/A
- GNLX N/A
- Industry
- GOCO Specialty Insurers
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- GOCO Finance
- GNLX Health Care
- Exchange
- GOCO Nasdaq
- GNLX Nasdaq
- Market Cap
- GOCO 95.6M
- GNLX 103.6M
- IPO Year
- GOCO 2020
- GNLX 2023
- Fundamental
- Price
- GOCO $11.92
- GNLX $2.36
- Analyst Decision
- GOCO Hold
- GNLX Strong Buy
- Analyst Count
- GOCO 1
- GNLX 4
- Target Price
- GOCO $13.00
- GNLX $18.25
- AVG Volume (30 Days)
- GOCO 33.6K
- GNLX 169.7K
- Earning Date
- GOCO 11-07-2024
- GNLX 11-14-2024
- Dividend Yield
- GOCO N/A
- GNLX N/A
- EPS Growth
- GOCO N/A
- GNLX N/A
- EPS
- GOCO N/A
- GNLX N/A
- Revenue
- GOCO $686,459,000.00
- GNLX $8,000.00
- Revenue This Year
- GOCO $1.14
- GNLX N/A
- Revenue Next Year
- GOCO $7.78
- GNLX N/A
- P/E Ratio
- GOCO N/A
- GNLX N/A
- Revenue Growth
- GOCO 30.17
- GNLX N/A
- 52 Week Low
- GOCO $7.27
- GNLX $1.60
- 52 Week High
- GOCO $16.44
- GNLX $16.60
- Technical
- Relative Strength Index (RSI)
- GOCO 54.43
- GNLX 37.36
- Support Level
- GOCO $10.65
- GNLX $2.86
- Resistance Level
- GOCO $12.98
- GNLX $3.07
- Average True Range (ATR)
- GOCO 0.82
- GNLX 0.31
- MACD
- GOCO -0.06
- GNLX -0.07
- Stochastic Oscillator
- GOCO 40.97
- GNLX 2.56
About GOCO GoHealth Inc.
GoHealth Inc is a health insurance marketplace in America. Its technology platform leverages modern machine-learning algorithms and helps individuals find the best health insurance plan for their specific needs. The company operates in single operating segment.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.